However, the recent generation of mTOR inhibitors directed simultaneously against the two branches of the network (mTORC1 and mTORC2) a.k.a. Rapalinks, have shown great therapeutic potential in an experimental trial of GBM [22]. This evidence concerns the gene MTOR and glioblastoma.